15.1.2025 11:01:37 CET | Thor Medical ASA | Flagging

Oslo, Norway, 15 January 2025: Reference is made to the stock exchange
announcement by Thor Medical ASA (the "Company") on 11 December 2024 regarding a
private placement of new shares to be issued by the Company (the "Private
Placement") and stock exchange announcement by the Company on 6 January 2025
regarding disclosure of share lending.

In connection with the registration of the share capital increase pertaining to
tranche 2 ("Tranche 2") of the Private Placement, the manager has redelivered a
total of 11,396,380 borrowed shares to Scatec Innovation AS, close associate of
primary insider of the Company John Andersen.

During the term of the loan, and prior to the redelivery of the shares, Scatec
Innovation AS' shareholding in the Company was reduced to 54,605,876, equivalent
to approx. 19.5% of the issued share capital and votes. Upon redelivery of the
borrowed shares and delivery of the 12,000,000 new shares allocated to Scatec
Innovation AS in Tranche 2, Scatec Innovation AS' holding of shares in the
Company is 78,002,256, equivalent to approx. 25.7 % of the issued share capital
and votes. Consequently, Scatec Innovation AS has crossed above the 20% and 25%
thresholds pursuant to section 4-2 (1) and (3) of the Norwegian Securities
Trading Act.

In addition, Scatec Innovation AS has controlling interest in Scatec Invest IV
AS, which holds 3,165,920 shares in the Company. Scatec Innovation AS aggregated
holding of shares is thus 81,168,176, of which 6,849,880 shares is held by
Scatec Innovation AS on behalf of Thorium Foundation as the beneficial owner of
the shares, equivalent to approx. 26.7% of the shares and votes in the Company.

This announcement is published in accordance with section 4-2 of the Norwegian
Securities Trading Act and is subject to disclosure requirements pursuant to the
EU Market Abuse Regulation article 19 (3) and the Norwegian Securities Trading
Act section and 5-12.

 

Contacts

Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, 
brede.ellingseter@thormedical.com

 

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.no - http://www.thormedical.no - 
https://www.thormedical.no.

VEDLEGG

Last ned som PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18385729/5532/Last%20ned%20som%20
PDF.pdf

Primary insider notification - Re-delivery of lent tranche 2 shares.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18385729/5531/Primary%20insider%2
0notification%20-%20Re-delivery%20of%20lent%20tranche%202%20shares.pdf